MCID: LWC001
MIFTS: 38

Low Compliance Bladder

Categories: Nephrological diseases

Aliases & Classifications for Low Compliance Bladder

MalaCards integrated aliases for Low Compliance Bladder:

Name: Low Compliance Bladder 12 15 74
Hyperactivity of Bladder 12
Hypertonicity of Bladder 12
Low Bladder Compliance 12
Hypertonic Bladder 12
Overactive Bladder 74

Classifications:



External Ids:

Disease Ontology 12 DOID:12144
ICD9CM 36 596.52
SNOMED-CT 69 9009001

Summaries for Low Compliance Bladder

MalaCards based summary : Low Compliance Bladder, also known as hyperactivity of bladder, is related to hydronephrosis and cystitis, and has symptoms including dysuria, prostatism and urgency of micturition. An important gene associated with Low Compliance Bladder is CHRM3 (Cholinergic Receptor Muscarinic 3), and among its related pathways/superpathways are Peptide ligand-binding receptors and Salivary secretion. The drugs Oxybutynin and Fesoterodine have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and spinal cord.

Related Diseases for Low Compliance Bladder

Diseases related to Low Compliance Bladder via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 hydronephrosis 9.8
2 cystitis 9.8
3 ureteral obstruction 9.8
4 neurogenic bladder 9.5 P2RX1 P2RX2

Comorbidity relations with Low Compliance Bladder via Phenotypic Disease Network (PDN):


Acute Cystitis Hypertension, Essential
Prostatic Hypertrophy

Symptoms & Phenotypes for Low Compliance Bladder

UMLS symptoms related to Low Compliance Bladder:


dysuria, prostatism, urgency of micturition, lower urinary tract symptoms

Drugs & Therapeutics for Low Compliance Bladder

Drugs for Low Compliance Bladder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 273)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxybutynin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 5633-20-5 4634
2
Fesoterodine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 286930-02-7, 286930-03-8 6918558
3
Mirabegron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 223673-61-8 9865528
4
Doxazosin Approved Phase 4 74191-85-8 3157
5
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
6
Tamsulosin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 106133-20-4 129211
7
Acetaminophen Approved Phase 4 103-90-2 1983
8
Propiverine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 60569-19-9 4942
9
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
10
Azithromycin Approved Phase 4 83905-01-5 55185 447043
11
Citalopram Approved Phase 4 59729-33-8 2771
12
Darifenacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 133099-04-4 444031
13
Belladonna Approved, Experimental Phase 4
14
Morphine Approved, Investigational Phase 4 57-27-2 5288826
15
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
16
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2 2180-92-9, 38396-39-3 2474
17
Meperidine Approved Phase 4 57-42-1 4058
18
Tenoxicam Approved Phase 4 59804-37-4 5312154
19
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
20
carbamide peroxide Approved Phase 4 124-43-6
21
Silodosin Approved Phase 4 160970-54-7
22
leucovorin Approved Phase 4 58-05-9 6006 143
23
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3 137-58-6 3676
24
Baclofen Approved Phase 4,Phase 3 1134-47-0 2284
25
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
26
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
27
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
28
Sulfamethoxazole Approved Phase 4 723-46-6 5329
29
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
30
Ofloxacin Approved Phase 4,Phase 1 82419-36-1 4583
31
Levofloxacin Approved, Investigational Phase 4,Phase 1 100986-85-4 149096
32
Lornoxicam Approved, Investigational Phase 4 70374-39-9 5282204
33
Piroxicam Approved, Investigational Phase 4 36322-90-4 5280452 54676228
34
Opium Approved, Illicit Phase 4 8008-60-4
35
Loperamide Approved Phase 4 53179-11-6 3955
36
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
37
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
38
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
39
BCG vaccine Investigational Phase 4
40 Parasympatholytics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Solifenacin succinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 242478-38-2
48 Anti-Infective Agents, Urinary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Muscarinic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Renal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 653)
# Name Status NCT ID Phase Drugs
1 Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder Unknown status NCT01423838 Phase 4 Solifenacin;Oxybutynin
2 Premarin Versus Toviaz for Treatment of Overactive Bladder Unknown status NCT01613170 Phase 4 Toviaz;Premarin;Placebo cream
3 MIrabegron With oveRACtive bLadder Symptoms in mEn Unknown status NCT02361502 Phase 4 mirabegron;placebo
4 Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients Unknown status NCT01876186 Phase 4 Solifenacin for 12 weeks;Solifenacin for 24 weeks
5 Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) Unknown status NCT00922506 Phase 4 doxazosin plus tolterodine SR
6 Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes Unknown status NCT02540707 Phase 4 solifenacin;mirabegron
7 Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome Unknown status NCT00313924 Phase 4 DETRUSITOL
8 Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele Unknown status NCT00175123 Phase 4 Botulinum A toxin
9 Botulinum Toxin in the Treatment of Idiopathic Detrusor Overactivity Unknown status NCT02009540 Phase 4 Botulinum toxin injected to bladder body;Botulinum toxin injected into trigone
10 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4 Botulinum Toxin
11 Ureteral Stent-related Pain and Mirabegron (SPAM) Trial Unknown status NCT02095665 Phase 4 Mirabegron;Tamsulosin;Tylenol #3
12 Pharmacological vs Surgical Treatment for Mixed Incontinence Unknown status NCT00523068 Phase 4 Tolterodine
13 A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB) Completed NCT02138747 Phase 4 Mirabegron;Tolterodine ER
14 Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder Completed NCT01578304 Phase 4 Imidafenacin;Fesoterodine
15 Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder Completed NCT03558919 Phase 4 Mirabegron 25mg;Solifenacin Succinate 5 MG
16 Therapy of the Overactive Bladder Syndrome Completed NCT01314781 Phase 4 solifenacin
17 Microorganism in Overactive Bladder Patients Completed NCT00883818 Phase 4 azithromycin, doxycycline
18 Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder Completed NCT00903045 Phase 4 Propiverine hydrochloride;Placebo
19 Over Active Bladder Patients Having Sling Surgery Completed NCT00852696 Phase 4 Solifenacin
20 Efficacy and Safety of Selective Serotonin Reuptake Inhibitor (SSRI) in Overactive Bladder Patients Completed NCT00902421 Phase 4 Selective serotonin reuptake inhibitors;Antimuscarinics
21 A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO) Completed NCT02092181 Phase 4 Mirabegron;Placebo
22 Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome Completed NCT01824420 Phase 4 Detrusitol 4mg QD and Oxybutynin ER 5mg QD;Detrusitol 4mg QD
23 A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder Completed NCT00928070 Phase 4 Fesoterodine;Placebo
24 Overactive Bladder Innovative Therapy Trial (OrBIT) Completed NCT00448175 Phase 4 Tolterodine
25 Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) Completed NCT00431041 Phase 4 solifenacin;oxybutynin immediate release
26 Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease Completed NCT01018264 Phase 4 solifenacin succinate (VESIcare);placebo
27 OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder Completed NCT01945489 Phase 4 Normal saline
28 Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients Completed NCT00730535 Phase 4 Tolterodine;Tolterodine;Tolterodine 6
29 Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event. Completed NCT02468375 Phase 4 mirabegron 50mg
30 Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder Completed NCT00171184 Phase 4 Darifenacin;Placebo
31 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) Completed NCT02216214 Phase 4 Mirabegron;Placebo
32 A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks Completed NCT00884104 Phase 4 Solifenacin
33 InSite for Over Active Bladder Completed NCT00547378 Phase 4 Standard Medical Therapy
34 Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder Completed NCT00366002 Phase 4 Darifenacin
35 Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron. Completed NCT02294396 Phase 4 Mirabegron tablet;Solifenacin tablet;Propiverine tablet;Imidafenacin tablet;Tolterodine capsule
36 Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms Completed NCT02715024 Phase 4 Tamsulosin;Solifenacin
37 Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder Completed NCT00836381 Phase 4 Tolterodine extended-release (ER) 4mg;Placebo
38 Reproducibility Study of OABSS and Its Response to Treatment Completed NCT02667470 Phase 4 Solifenacin
39 The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB) Completed NCT01533597 Phase 4 Solifenacin;Solifenacin plus Tamsulosin
40 Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life Completed NCT00573508 Phase 4 Placebo;Solifenacin Succinate
41 Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder Completed NCT00127270 Phase 4 Darifenacin;Darifenacin
42 A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment Completed NCT01318837 Phase 4 solifenacin
43 Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia Completed NCT00771394 Phase 4 Tamsulosin hydrochloride;Solifenacin succinate
44 An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants Completed NCT00613327 Phase 4 Oxybutynin chloride OROS
45 A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine. Completed NCT01302054 Phase 4 Fesoterodine 8 mg;Placebo
46 A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients Completed NCT01745094 Phase 4 mirabegron;solifenacin
47 A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency Completed NCT00911937 Phase 4 Fesoterodine;Placebo
48 A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder. Completed NCT00798434 Phase 4 Placebo;Fesoterodine fumarate
49 Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence Completed NCT01194999 Phase 4
50 Detrol LA In Men With Overactive Bladder. Completed NCT00282932 Phase 4 Detrol LA

Search NIH Clinical Center for Low Compliance Bladder

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Low Compliance Bladder

Anatomical Context for Low Compliance Bladder

MalaCards organs/tissues related to Low Compliance Bladder:

42
Prostate, Testes, Spinal Cord, Brain, Bone, Heart, Smooth Muscle

Publications for Low Compliance Bladder

Articles related to Low Compliance Bladder:

# Title Authors Year
1
Low compliance bladder. ( 27343340 )
2016
2
URB937, a peripherally restricted inhibitor for fatty acid amide hydrolase, reduces prostaglandin E2 -induced bladder overactivity and hyperactivity of bladder mechano-afferent nerve fibres in rats. ( 26189783 )
2016
3
Video-urodynamic effects of mirabegron, a I^3 -adrenoceptor agonist, in patients with low-compliance bladder. ( 26177781 )
2015
4
Low compliance bladder plays a role in hydronephrosis in lupus cystitis: a case report. ( 24596124 )
2014
5
Laparoscopic diverticulocystoplasty for low compliance bladder in a child. ( 23318084 )
2012
6
Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder. ( 20969642 )
2010
7
Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions. ( 16271557 )
2005
8
Significance of low compliance bladder in cauda equina injury. ( 12483499 )
2002
9
Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. ( 11204266 )
2000
10
Gastrocystoplasty in a woman with radiation-induced ureteral obstruction and low-compliance bladder. ( 9792987 )
1998

Variations for Low Compliance Bladder

Expression for Low Compliance Bladder

Search GEO for disease gene expression data for Low Compliance Bladder.

Pathways for Low Compliance Bladder

GO Terms for Low Compliance Bladder

Cellular components related to Low Compliance Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.26 ADRB3 CHRM3 P2RX1 P2RX2
2 postsynapse GO:0098794 9.16 P2RX1 P2RX2
3 integral component of nuclear inner membrane GO:0005639 8.62 P2RX1 P2RX2

Biological processes related to Low Compliance Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to organic substance GO:0010033 9.46 P2RX1 P2RX2
2 cation transport GO:0006812 9.43 P2RX1 P2RX2
3 excitatory postsynaptic potential GO:0060079 9.4 P2RX1 P2RX2
4 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.37 ADRB3 CHRM3
5 cation transmembrane transport GO:0098655 9.32 P2RX1 P2RX2
6 regulation of vasoconstriction GO:0019229 9.26 CHRM3 P2RX1
7 response to ATP GO:0033198 9.16 P2RX1 P2RX2
8 purinergic nucleotide receptor signaling pathway GO:0035590 8.96 P2RX1 P2RX2
9 regulation of vascular smooth muscle contraction GO:0003056 8.62 CHRM3 P2RX1

Molecular functions related to Low Compliance Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion channel activity GO:0005216 9.32 P2RX1 P2RX2
2 drug binding GO:0008144 9.26 CHRM3 P2RX1
3 extracellularly ATP-gated cation channel activity GO:0004931 9.16 P2RX1 P2RX2
4 ATP-gated ion channel activity GO:0035381 8.96 P2RX1 P2RX2
5 purinergic nucleotide receptor activity GO:0001614 8.62 P2RX1 P2RX2

Sources for Low Compliance Bladder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....